Anti-obesity drug therapy can be offered as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or 2730 kg/m 2 in the presence of at least one weight-related comorbidity, e.g., dysglycemia, hypertension, dyslipidemia, or obstructive sleep apnea
Insulin resistance and diabetes mellitus in Alzheimers disease
It offers a way to ease in, stay consistent, and get results
These factors have led to the ADA/EASD recommendation that GLP-1 RAs be the preferred first injectable glucose-lowering agent for T2D (ahead of insulin therapy
54 This trial emphasized that orforglipron might provide an alternative to injectable GLP-1 receptor agonists and oral semaglutide, with the prospect of less burdensome administration to achieve treatment goals in diabetics
Clinical Applications Type 2 Diabetes Management Glucagon-like peptide-1 (GLP-1) agonists have emerged as a crucial class of medications for managing type 2 diabetes, a chronic condition characterized by insulin resistance and impaired glucose regulation
